Micronuclei are known potent activators of the cGAS/STING pathway, which drives type 1 interferon production, providing a rationale for leveraging existing DNA checkpoint inhibitors as a novel means of eliciting an immunological anti-tumour response in combination with low-dose radiotherapy. This evidence concerns the gene CGAS and neoplasm.